Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-08-07 DOI:10.1111/bjh.19698

Samantha A. Hershenfeld, Josuha W.D. Tobin, Victoria Shelton, Lourdes Calvente, Katherine Lajkosz, Ting Liu, Marianne Brodtkorb, Francesco Annibale d'Amore, Maja Ludvigsen, Tara Baetz, David LeBrun, Nathalie Johnson, Michael Crump, Michael Hong, John Kuruvilla, Rosemarie Tremblay-LeMay, Michael MacManus, Richard Tsang, David C. Hodgson, Maher K. Gandhi, Robert Kridel

{"title":"Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy","authors":"Samantha A. Hershenfeld, Josuha W.D. Tobin, Victoria Shelton, Lourdes Calvente, Katherine Lajkosz, Ting Liu, Marianne Brodtkorb, Francesco Annibale d'Amore, Maja Ludvigsen, Tara Baetz, David LeBrun, Nathalie Johnson, Michael Crump, Michael Hong, John Kuruvilla, Rosemarie Tremblay-LeMay, Michael MacManus, Richard Tsang, David C. Hodgson, Maher K. Gandhi, Robert Kridel","doi":"10.1111/bjh.19698","DOIUrl":null,"url":null,"abstract":"Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1810-1814"},"PeriodicalIF":5.1000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19698","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.19698","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.

Abstract Image

查看原文本刊更多论文

接受放射治疗的局限期滤泡性淋巴瘤的单基因突变与预后。

放疗是治疗局限期滤泡性淋巴瘤（FL）的常规方法，但半数患者最终会复发。我们假设，特定基因突变的存在可能会预测预后。我们对117例接受放疗的局限期滤泡性淋巴瘤患者进行了69个基因的靶向测序，发现了反复发生突变的基因。CREBBP是最常发生突变的基因，突变的CREBBP与较差的无进展生存期相关，但经误诊率调整后并不相关。这种关联未能在一个独立队列中得到验证。我们的结论是，复发性基因突变并不能预测这种情况下的预后。替代生物标志物可能会提供更好的预后洞察力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.